search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
MICROBIOLOGY


Faster diagnostics is the key to improving sepsis care


The bioMérieux UK Sepsis Summit recently raised awareness of diagnostic strategies that can help improve outcomes for patients with sepsis. During the conference, the Royal Berkshire NHS Foundation Trust shared an insight into a trial of innovative technology that reduced time to identification of pathogens – optimising antibiotic prescribing, reducing length of hospital stay, and improving patient outcomes.


Olubunmi Martindale-Sheldon, Directorate Manager, Pathology and Pharmacy, Royal Berkshire NHS Foundation Trust, speaking at the UK Sepsis Summit.


WWW.PATHOLOGYINPRACTICE.COM MAY 2024


Innovative solutions for sepsis diagnosis were high on the agenda at the UK Sepsis Summit – with valuable insights provided by hospital trusts into the latest improvement initiatives. Hosted by bioMérieux, at the University of Nottingham, the event provided an opportunity for multiple stakeholders engaged within the sepsis patient pathway to come together and share best practice. Discussions highlighted that a collaborative, integrated and optimised pathway is crucial to enable informed clinical decision-making and improved patient pathways. But could novel solutions in syndromic testing also take patient care to the next level? During the two-day event, Olubunmi Martindale-Sheldon, Directorate Manager, Pathology and Pharmacy, Royal Berkshire NHS Foundation Trust, delivered a presentation titled: “Innovative solutions for sepsis diagnosis and treatment – leveraging the potential of BioFire Technology”. Her presentation included discussion of the blood culture pathway, critical control points, and the challenges with sepsis diagnosis and treatment. Olubunmi also shared the findings of a recent trial of BioFire, including some success stories where the management of patients had been optimised through the adoption of the technology.


Olubunmi explained that the Royal 55


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60